Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

Rituximab improves outcomes for persons with lymphoproliferative disorders and is increasingly used to treat immune-mediated illnesses. Recent reports describe 2 patients with systemic lupus erythematosus and 1 with rheumatoid arthritis who developed progressive multifocal leukoencephalopathy (PML) after rituximab treatment. We reviewed PML case descriptions among patients treated with rituximab from the Food and Drug Administration, the manufacturer, physicians, and a literature review from 1997 to 2008. Overall, 52 patients with lymphoproliferative disorders, 2 patients with systemic lupus erythematosus, 1 patient with rheumatoid arthritis, 1 patient with an idiopathic autoimmune pancytopenia, and 1 patient with immune thrombocytopenia developed PML after treatment with rituximab and other agents. Other treatments included hematopoietic stem cell transplantation (7 patients), purine analogs (26 patients), or alkylating agents (39 patients). One patient with an autoimmune hemolytic anemia developed PML after treatment with corticosteroids and rituximab, and 1 patient with an autoimmune pancytopenia developed PML after treatment with corticosteroids, azathioprine, and rituximab. Median time from last rituximab dose to PML diagnosis was 5.5 months. Median time to death after PML diagnosis was 2.0 months. The case-fatality rate was 90%. Awareness is needed of the potential for PML among rituximab-treated persons.

[1]  Ludwig Kappos,et al.  Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring , 2007, The Lancet Neurology.

[2]  F. Guerini,et al.  JC virus viremia in interferon-β-treated and untreated Italian multiple sclerosis patients and healthy controls , 2011, Journal of NeuroVirology.

[3]  D. Clifford,et al.  The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: Defining a consensus terminology , 2011, Journal of NeuroVirology.

[4]  H. Hartung.  New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab , 2009, The Lancet Neurology.

[5]  G. Kronborg,et al.  Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. , 2009, The Journal of infectious diseases.

[6]  Michael E. Williams.  Rituximab and Progressive Multifocal Leukoencephalopathy , 2009 .

[7]  D. Bourdette,et al.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis , 2008, Current neurology and neuroscience reports.

[8]  K. Tobinai,et al.  Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature , 2008, International journal of hematology.

[9]  W. Chan,et al.  Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Marcus,et al.  Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Kai-Hsin Chang,et al.  Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. , 2008, Blood.

[12]  H. Hartung,et al.  The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. , 2008, Blood.

[13]  L. Kappos,et al.  Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients , 2008, Journal of Neuroimmunology.

[14]  M. Klimpfinger,et al.  Progressive multifocal leukoencephalopathy after rituximab in a patient with relapsed follicular lymphoma and low IgG levels and a low CD4+ lymphocyte count , 2008, Leukemia & lymphoma.

[15]  H. Harris.  Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab. , 2007, Rheumatology.

[16]  D. Focosi,et al.  Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature , 2008, Annals of Hematology.

[17]  S. Amadori,et al.  Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. , 2007, Blood.

[18]  R. Bouabdallah,et al.  JC papovavirus leukoencephalopathy after first line treatment with CHOP and rituximab , 2007, Haematologica.

[19]  E. Mowry,et al.  PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY AFTER RITUXIMAB IN A CASE OF NON-HODGKIN LYMPHOMA , 2007, Neurology.

[20]  J. Baehring,et al.  Progressive multifocal leukoencephalopathy in a patient with marginal zone B-cell lymphoma , 2007, Journal of Neuro-Oncology.

[21]  L. Kappos,et al.  Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring , 2007, The Lancet Neurology.

[22]  Denys T. Lau,et al.  Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. , 2007, Archives of internal medicine.

[23]  A. Levinson,et al.  Progressive multifocal leukoencephalopathy in a patient with common variable immunodeficiency and abnormal CD8+ T-cell subset distribution. , 2007, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[24]  D. Isenberg,et al.  B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response , 2007, Annals of the rheumatic diseases.

[25]  S. Torp,et al.  Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature. , 2007, Clinical neuropathology.

[26]  F. Dentali,et al.  Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura , 2007, Annals of Internal Medicine.

[27]  H. Harputluoglu,et al.  Rituximab-related viral infections in lymphoma patients , 2007, Leukemia & lymphoma.

[28]  Stanley B. Cohen,et al.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.

[29]  G. Martinelli,et al.  Peripheral T-lymphocyte subsets in patients treated with Rituximab–Chlorambucil combination therapy for indolent NHL , 2006, Annals of Hematology.

[30]  A. López-Guillermo,et al.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.

[31]  R. Abdulqawi,et al.  Progressive multifocal leucoencephalopathy in a case of chronic lymphocytic leukaemia , 2006 .

[32]  I. Krsnik,et al.  Changes in the natural history of progressive multifocal leukoencephalopathy in HIV‐negative lymphoproliferative disorders: Impact of novel therapies , 2005, American journal of hematology.

[33]  M. M. Hasan,et al.  Progressive multifocal leucoencephalopathy in a case of chronic lymphocytic leukaemia , 2005, British journal of haematology.

[34]  K. Tyler,et al.  Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. , 2005, The New England journal of medicine.

[35]  P. Rutgeerts,et al.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. , 2005, The New England journal of medicine.

[36]  S. Atlas,et al.  Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. , 2005, The New England journal of medicine.

[37]  P. Gaulard,et al.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Matthew H Samore,et al.  The Research on Adverse Drug Events and Reports (RADAR) project. , 2005, JAMA.

[39]  M. Frosch,et al.  Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14-2004. A 66-year-old man with progressive neurologic deficits. , 2004, The New England journal of medicine.

[40]  Y. Hirose,et al.  Progressive Multifocal Leukoencephalopathy in a Patient with X-linked Agammaglobulinemia , 2003, Scandinavian journal of infectious diseases.

[41]  M. Steurer,et al.  Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation rituximab. , 2003, Transplantation.

[42]  J. Seymour,et al.  Progressive Multifocal Leukoencephalopathy Complicating Waldenström's Macroglobulinaemia , 2003, Leukemia & lymphoma.

[43]  E. Major,et al.  Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. , 2002, The Journal of infectious diseases.

[44]  A. Pecora,et al.  Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. , 2002, Blood.

[45]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[46]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[47]  H. Petry,et al.  Cellular and humoral immune response in progressive multifocal leukoencephalopathy , 2001, Annals of neurology.

[48]  Berger,et al.  Progressive Multifocal Leukoencephalopathy. , 2020, Current treatment options in neurology.

[49]  E. Major,et al.  AIDS- and non–AIDS-related PML association with distinct p53 polymorphism , 2000, Neurology.

[50]  F. Bolgert,et al.  Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP). , 1999, Hematology and cell therapy.

[51]  R. Holman,et al.  Progressive Multifocal Leukoencephalopathy in the United States, 1979–1994: Increased Mortality Associated with HIV Infection , 1998, Neuroepidemiology.

[52]  J. Icart,et al.  Prevalence of JC virus viraemia in HIV-infected patients with or without neurological disorders: a prospective study. , 1998, Journal of neurovirology.

[53]  I. Fong,et al.  Diagnostic value of detecting JC virus DNA in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy , 1995, Journal of clinical microbiology.

[54]  E. Major,et al.  Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain , 1992, Clinical Microbiology Reviews.

[55]  R. Scully,et al.  Case records of the Massachusetts General Hospital. , 1990 .

[56]  C. Kufta,et al.  Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. , 1988, The New England journal of medicine.

[57]  S. Gardner,et al.  Use of a molecular probe for detecting JCV DNA directly in human brain material , 1986, Journal of medical virology.

[58]  E. Mancall,et al.  Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. , 1958, Brain : a journal of neurology.